Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial
Authors' conclusion
Both insulins produce comparable outcomes in type 2 diabetes subphenotypes, but in SIDD, add-on treatment to basal insulin is required to achieve glycaemic targets.
Study context
- Population
- Insulin-naive participants with T2D from EDITION 3, assigned to subphenotypes Mild Obesity Diabetes (MOD), Severe Insulin Deficient Diabetes (SIDD), Mild Age-Related Diabetes (MARD), Severe Insulin Resistant Diabetes (SIRD)insulin-naive · assigned to subphenotypes MOD 481 · SIDD 190 · MARD 156 · SIRD 26
- Participants
- 858 participants
- Comparison
- IGlar-300 vs IGlar-100 in T2D subphenotypes
Methodological detailssubphenotype analysis
- Subphenotype analysis
Primary result
As reported in the abstract
26 weeks
MARD and MOD: similar HbA1c decrease with both insulins
16-19 mmol/mol
MARD and MOD: similar fasting plasma glucose (FPG) decrease with both insulins
1.4-1.7 mmol/L
SIDD: HbA1c at week 26 suboptimal despite highest basal insulin doses
57-60 mmol/mol/7.3-7.6%
Safety
| Outcome | OR (95% CI) | |
|---|---|---|
| Level 1 nocturnal hypoglycaemia, MOD | 0.59 (0.36–0.97) | |
| Level 1 nocturnal hypoglycaemia, SIDD | 0.49 (0.24–0.99) | |
| Level 2 hypoglycaemia at any time, SIDD | 0.31 (0.13–0.77) | |
| 0.10.31310Odds ratio (log scale) |
Original publication
Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial. Diabetes Obes Metab. Published 20 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →